Devyser Diagnostics AB (DVYSR.ST) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Sweden · ISIN SE0016588867

Price
65.00 SEK
Market cap
1.08 bn SEK
P/E (2025)
–
P/S (2025)
4.31
Dividend yield
0.00 %
Net margin
-3.35 %
Return on equity (ROE)
-2.37 %
Return on assets (ROA)
-1.79 %

Devyser Diagnostics AB financials

Fiscal year20242025
Revenue216.90 m SEK250.50 m SEK
Gross profit172.70 m SEK201.90 m SEK
Operating income-58.30 m SEK10.60 m SEK
EBIT-54.10 m SEK10.60 m SEK
Net income-61.50 m SEK-8.40 m SEK
Diluted EPS – continuing operations-3.75 SEK-0.51 SEK

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.